Health
A failed trial for a heart drug casts shadow over rivals developing similar therapies
By Katherine Langford
FDA flags potential vision loss risk linked to GLP-1 drugs: What users of weight-loss medications should know
Katherine Langford
Katherine Langford
Editor-in-Chief · Edina, MN
Katherine oversees editorial operations across all six brands. Before joining The Meridan Group, she spent 14 years at the Minneapolis Star Tribune, where she led the metro desk through its digital transformation. She holds a Master's in Journalism from Northwestern's Medill School.
More from Katherine →Editor-in-Chief · Tuesday, November 10, 2026 at 10:18 AM · 1 min read
An FDA analysis of 126 clinical trials involving 134,253 participants found higher NAION incidence among GLP-1 drug users than among those taking placebos or other diabetes medications.
Up nextA failed trial for a heart drug casts shadow over rivals developing similar therapiesHealth · 1 min read
